Eye Center Uzwil, Uzwil, Switzerland.
Graefes Arch Clin Exp Ophthalmol. 2010 Nov;248(11):1667-70. doi: 10.1007/s00417-010-1380-3. Epub 2010 May 28.
To present the effect of intravitreal ranibizumab (Lucentis®) therapy in a patient suffering from retinal macroaneurysm.
Case report. An 82-year-old female patient was diagnosed with retinal macroaneurysm of the inferior temporal artery with macular edema. Functional and morphological data at baseline and at 4 weeks, 3 months, and 5 months after the initiation of therapy with two intravitreal ranibizumab (Lucentis®) injections followed by focal argon laser coagulation surrounding the retinal macroaneurysm are presented.
Best-corrected visual acuity improved from 20/50 at baseline to 20/20 at 3-month follow-up and maintained stable at 20/25 through 5-month follow-up. Central retinal thickness measured by optical coherence tomography decreased from 510 µm at baseline to 148 µm at 5-month follow-up. Fluorescein angiography demonstrated closure of the retinal macroaneurysm at 6-week follow-up. No ocular or systemic side effects were detected.
Intravitreal ranibizumab (Lucentis®) therapy may close the retinal macroaneurysm leading to resolution of the associated macular edema and consequently visual improvement. To our knowledge, this is the first case of a retinal macroaneurysm benefiting from treatment with intravitreal ranibizumab (Lucentis®). The observed results warrant further investigation.
介绍玻璃体腔雷珠单抗（Lucentis®）治疗视网膜大动脉瘤患者的效果。
病例报告。一位 82 岁女性患者被诊断为颞下动脉视网膜大动脉瘤伴黄斑水肿。基线时以及治疗开始后 4 周、3 个月和 5 个月时，分别对患者进行了两次玻璃体腔雷珠单抗（Lucentis®）注射治疗，并在视网膜大动脉瘤周围进行了局部氩激光凝固治疗，记录了其功能和形态数据。
最佳矫正视力从基线时的 20/50 提高到 3 个月随访时的 20/20，并在 5 个月随访时稳定在 20/25。光学相干断层扫描测量的中心视网膜厚度从基线时的 510µm 下降到 5 个月随访时的 148µm。荧光素血管造影显示视网膜大动脉瘤在 6 周随访时已经闭合。未发现眼部或全身副作用。
玻璃体腔雷珠单抗（Lucentis®）治疗可能会使视网膜大动脉瘤闭合，从而使相关黄斑水肿消退，视力得到改善。据我们所知，这是首例视网膜大动脉瘤受益于玻璃体腔雷珠单抗（Lucentis®）治疗的病例。观察到的结果值得进一步研究。
